



Byotrol Plc

("Byotrol" or the "Company")

Patent Granted for Novel Anti-viral Seaweed Extract

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, is pleased to report the approval today of a UK patent following its discovery of unique anti-viral properties of certain enhanced extracts of commonly available brown seaweed.

The award is a result of many years of research by Byotrol's technical team at its laboratories at Thornton Science Park, a University of Chester campus, and has been supported by the research scientists at the University of Liverpool led by Professor James Stewart, and by funding received from the Biotechnology and Biological Sciences Research Council (BBSRC) and Innovate UK.

The grant of the patent application gives Byotrol validated, valuable and protected intellectual property, to support the development of commercial relationships.

In the UK and Europe, seaweed extracts are not as yet approved as active materials for biocidal products, Byotrol's established area of expertise. So, we are now actively exploring alternative applications in very sizeable markets such as over-the-counter (OTC) products for the prophylactic treatment of viral conditions including colds, flu, coronaviruses and cold sores.

Byotrol Plc's Chairman Dr Trevor Francis comments:

We are delighted to have secured the first patent for our seaweed-based anti-viral technologies. It is another good indication of the quality of our technical capability, and it will most certainly help us as we intensify the search for commercial partners. It also adds to our already significant level of intellectual property in antimicrobials.

This patent further confirms Byotrol's commitment to developing and commercializing natural and sustainable antimicrobial actives.

For further information contact:

Byotrol Plc

Dr Trevor Francis, Non- Executive Chairman
Vivan Pinto, Chief Executive Officer
Chris Sedwell, Chief Financial Officer

+44 (0)1925 742 000

finnCap Limited (Nominated Adviser and Broker)

Geoff Nash/George Dollemore – Corporate Finance
Nigel Birks/Harriet Ward – ECM

+44 (0)20 7220 0500

Flagstaff Strategic and Investor Communications
Tim Thompson/Andrea Seymour/Fergus Mellon

+44 (0)20 7129 1474
byotrol@flagstaffcomms.com

This announcement is released by Byotrol Plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Notes to editors

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

For more information, go to byotrol.com